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Article focus
  Provision of an abridged protocol for the 
WHiTE 3: HEMI study.
  Allow transparency of study methods 
and design.
Key messages
  Outcomes to be published late 2016.
Strengths and limitations
  Rigorous design.
  Optimal primary outcome measure for 
this patient cohort (EQ-5D).
Introduction
Proximal femoral (hip) fractures are one of 
the greatest challenges facing the medical 
community. In 1990, a global incidence of 
1.31 million was reported and was associ-
ated with 740 000 deaths.1 Hip fractures 
constitute a heavy socioeconomic burden 
worldwide. The cost of this clinical prob-
lem is estimated at 1.75 million disability 
adjusted life years lost, 1.4% of the total 
healthcare burden in established market 
economies.1
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Background
Approximately half of all hip fractures are displaced intracapsular fractures. The standard 
treatment for these fractures is either hemiarthroplasty or total hip arthroplasty. The recent 
national Institute for Health and care excellence (nIce) guidance on hip fracture manage-
ment recommends the use of ‘proven’ cemented stem arthroplasty with an orthopaedic 
Device evaluation panel (oDep) rating of at least 3B (97% survival at three years). The 
Thompsons prosthesis is currently lacking an oDep rating despite over 50 years of clinical 
use, likely due to the paucity of implant survival data. nationally, adherence to these guide-
lines is varied as there is debate as to which prosthesis optimises patient outcomes.
Design
This study design is a multi-centre, multi-surgeon, parallel, two arm, standard-of-care prag-
matic randomised controlled trial. It will be embedded within the WHiTe comprehensive 
cohort study (IsRcTn63982700). The main analysis is a two-way equivalence comparison 
between Hemi-Thompson and Hemi-exeter polished taper with Unitrax head. secondary 
outcomes will include radiological leg length discrepancy measured as per Bidwai and Wil-
lett, mortality, re-operation rate and indication for re-operation, length of index hospital 
stay and revision at four months. This study will be supplemented by the nHFD (national 
Hip Fracture Database) dataset.
Discussion
evidence on the optimum choice of prosthesis for hemiarthroplasty of the hip is lacking. 
national guidance is currently based on expert opinion rather than empirical evidence. The 
incidence of hip fracture is likely to continue to increase and providing high quality evidence 
on the optimum treatment will improve patient outcomes and have important health eco-
nomic implications.
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Existing knowledge
Hip fractures can be subdivided into intra and extracap-
sular fractures. Approximately half of all hip fractures are 
intracapsular, and the majority of these are displaced 
(Type AO/OTA B3).2,3 The accepted treatment for a dis-
placed intracapsular fracture is an arthroplasty. This 
includes hemiarthroplasty (HA), where the proximal 
femur is replaced, and total hip arthroplasty (THA), where 
both the femur and acetabulum are replaced.
The Thompson’s prosthesis is a press fit hemiarthro-
plasty implant designed in the pre-cement era. It is now 
most frequently cemented, with improved clinical effec-
tiveness compared with uncemented monoblock 
(Austin-Moore) stems.4 Its offset is fixed as it rests just 
above the lesser trochanter. In addition, the placement 
of the neck cut can be varied. The prevalence of leg 
length discrepancy following the use of a Thompson 
prosthesis is unknown. The Orthopaedic Device 
Evaluation Panel (ODEP) produces ratings for hip arthro-
plasty prostheses used in the united Kingdom, based on 
length of follow-up and quality of evidence. The 
Thompson’s stem currently does not have an ODEP rat-
ing, due to the relative paucity of implant survival data in 
this at-risk patient group.
The national Institute for Health and care Excellence 
(nIcE) offers evidence-based guidance to clinicians in the 
united Kingdom. The recent nIcE guidance on hip fracture 
management recommends the use of ‘proven’ cemented 
stem designs with an ODEP rating of at least 3B (97% sur-
vival at three years), instead of the Thompson’s prosthesis.5 
Recent evidence published since the nIcE guidance how-
ever supports the use of the Thompson stem.
The Thompsons stem has been used extensively in the 
united Kingdom for over 50 years. until recently, there 
has been a lack of evidence of implant survival but the 
implant is in common use in all the investigating units of 
this study and large series have recently been published 
demonstrating a low complication rate and excellent 
implant survival. One study of 430 patients followed to at 
least five years showed a dislocation rate of 1.4% and a 
revision rate of 1.2%.6 Another recent series of 1670 
patients followed to five years reported implant survival 
at 95.4% - equivalent to a higher ODEP 5 status.7
There are conflicting global trends for the use of 
Thompson’s prosthesis in favour of newer stems. A well-
constructed but underpowered study showed no differ-
ence in hip function, pain, complications or mortality at 12 
months.8 A recent review of the swedish Hip Arthroplasty 
Register has reported a decline in the proportion of 
Thompson’s stems from 9% to 1% from 2005 to 2009 
with an increasing number of unipolar modular prosthe-
ses being implanted.9 The 2011 annual report from the 
Australian national Joint Registry found that the use of the 
Thompson’s prosthesis had increased in 2010 (30.6% of 
all monoblocks, up from 20.9% in 2003),  however the 
number of monoblock stems was declining compared 
with monoblock modular and bipolar implants.10
The Exeter stem is a well proven design and is consist-
ent with current nIcE guidance. It allows for leg length 
adjustment and offset. One recent non-randomised study 
found that an unacceptable leg length discrepancy was 
1.4 times more likely to occur with the Thompsons stem 
compared with the Exeter Trauma stem,11 which is of a 
similar shape. leg length discrepancy has been shown in 
recent studies of hip replacement to influence both hip 
function (WOMAc) and health status (EQ-5D).12,13 The 
Exeter stem is also in common use in the investigating 
units of the current study.
Aim of the trial. The aim of this trial is to compare the 
health-related quality of life (HRQol) of patients receiv-
ing a cemented Thompsons versus an Exeter cemented 
polished taper stem for displaced intracapsular fractures 
of the proximal femur requiring hemiarthroplasty.
Good clinical practice. The trial will be carried out in 
accordance with good clinical practice (gcP) and in 
accordance with the following protocol.
CONSOrT recommendations. The trial will be reported 
in line with the cOnsORT statement.14
Trial design
Design summary. This study will be a multi-centre, multi-
surgeon, two-arm parallel group, randomised standard-
of-care controlled trial. It will be embedded within the 
WHiTE comprehensive cohort study (IsRcTn 63982700). 
The WHiTE study is a large cohort study examining a range 
of outcomes including the EQ-5D (validated health status 
measure).15 in patients following hip fracture. The WHiTE 
study allows embedding of randomised controlled trials 
within this patient cohort.16 The trial will include a two-
way equivalence comparison between Hemi-Thompson 
and Hemi-Exeter polished taper with unitrax head (stryker, 
Kalamazoo, Michigan). The trial is planned to last a total of 
28 months.
It is expected that participant recruitment will take 18 
months and final follow-up will be at four months. Based 
upon 2013 data in the national Hip Fracture Database 
(nHFD) the involved units perform approximately 890 of 
such procedures per year.
Trial management will be conducted at Warwick 
clinical Trials unit in accordance with standard operating 
procedures.
Hypothesis. The null hypothesis is that there is no dif-
ference in HRQol at four months post injury between 
patients over 60 years of age with an AO/OTA type B3 
fracture of the proximal femur treated with an Exeter pol-
ished taper/unitrax versus a Thompson hemiarthroplasty.
Objectives. The primary objective is:
 – To quantify and draw inferences on observed differ-
ences in patients’ HRQol between the trial treatment 
groups at four months post-injury.
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The secondary objectives are:
 – To quantify and draw inferences on observed differ-
ences in the functional outcomes between the trial 
treatment groups.
 – To quantify and draw inferences on observed differ-
ences in the proportion of all cause repeat surgery 
between the trial treatment groups.
 – To quantify and draw inferences on observed differ-
ences in the proportion of complications between the 
trial treatment groups.
Outcome assessment. We will augment the existing 
nHFD dataset with radiographic fracture pattern and 
EQ-5D-5l15 at baseline (retrospective pre- fracture) and 
120 days post-fracture. 120 days represents a routine 
follow-up point for the nHFD, and the point at which 
recovery following hip fracture plateaus. Parsons et al17 
reported that EQ-5D improved after surgery to around 
four months, with little evidence for subsequent improve-
ment after this time-point.
In addition, copies of the participants’ routine “opera-
tion note” and “discharge summary” will be collected. 
The discharge summary includes details of their treatment, 
peri-operative complications and discharge address.
Primary outcome measure. The primary objective of this 
trial is to quantify and draw inferences on patient’s HRQol 
between treatments based on observed differences as 
shown by a validated, patient-reported, quality of life ques-
tionnaire collected at four months post-injury – EQ-5D-5l. 
Proxy reporting of EQ-5D will be used in the event of par-
ticipants lacking capacity to consent. Parsons et al17 dem-
onstrated that an EQ-5D reported by proxies (relatives and 
carers) behaves similarly to self-reported scores.
The use of the EQ-5D as a primary outcome measure is 
based upon work that found that the EQ-5D increased 
until four months, at which point the EQ-5D plateaus. 
Between four and 12 months post-operative improve-
ment in the EQ-5D score was minimal. When this is bal-
anced against the gradually increasing mortality rates in 
this patient cohort, a follow-up time of four months has 
been decided upon, which will represent a point of maxi-
mum benefit from hip fracture surgery, whilst minimising 
loss to follow-up through mortality.
Secondary outcome measure. The secondary objectives 
of the study are to quantify and draw inferences on the 
efficacy of the group based on observed differences as 
shown by:
 – Radiological leg length discrepancy measured as per 
Bidwai and Willett;11
 – Mortality;
 – Re-operation and cause;
 – length of index hospital stay;
 – Revision at four months.
Participant outcomes will be collected at baseline (pre-
injury status recorded upon admission to hospital) and 
120 days post-surgery as per the current requirement for 
the nHFD. This will include data on delays to surgery and 
the surgeon’s seniority
Health economic measures. The patient-recorded out-
come data will be combined with mortality data extracted 
from the nHFD to estimate a quality-adjusted life year 
(QAly) profile for each patient. This will allow us to esti-
mate the production of health associated with the surgical 
procedures and treatment pathways for each participant.
Eligibility. Patients will be screened in the daily trauma 
meetings at each recruiting hospital.
Inclusion criteria
 – All patients presenting to the collaborative with an 
AO/OTA type B3 fracture of the hip.
 – Patients who the treating consultant Orthopaedic 
surgeon believe will benefit from hemiarthroplasty.
Exclusion criteria
 – Patients younger than 60 years of age;
 – Patients with pre-existing symptomatic hip arthritis;
 – Patients who are managed non-operatively.
Post-recruitment withdrawals and exclusions. Partici-
pants may withdraw from the study at any time without 
prejudice. The participants may be withdrawn from the 
study at the discretion of the chief Investigator due to 
safety concerns. Throughout the study, screening logs 
will be kept to determine the number of patients assessed 
for eligibility and reasons for any exclusion. Patients who 
decline to continue to take part will be given the oppor-
tunity to discuss/inform the research team of the reason-
ing behind their decision not to take part.
Consent. Patients with a hip fracture are a clinical priority 
for urgent operative care. They will undergo surgery on 
the next available trauma operating list. All patients with 
a fracture of the hip are in pain and have received opiate 
analgesia. It is therefore understandable that patients find 
the initial period of their treatment in hospital confusing 
and disorientating. similarly, patients’ next of kin, carers 
and friends are anxious at this time and may have dif-
ficulty in weighing the large amounts of information that 
they are given about the injury and plan for treatment.
In this emergency situation, the focus is on obtaining 
consent for surgery (where possible) and informing the 
patient and any next of kin about immediate clinical care. 
It is often not possible for the patient/consultee to review 
trial documentation, weigh the information and commu-
nicate an informed decision about whether they would 
wish to participate.
conducting research in this ‘emergency setting’ is reg-
ulated by the Mental capacity Act 2005.18 As patients are 
likely to lack capacity as described above, and because of 
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the urgent nature of the treatment limiting access to, and 
appropriate discussion with Personal consultees, we will 
act in accordance with section 32, subsection 9b of the 
Mental capacity Act following a process approved by the 
relevant research ethics committee. Those patients who 
have surgery on the next available trauma operating thea-
tre will enter the study under presumed consent; we will 
not obtain consent prior to surgery, but will approach an 
appropriate consultee. Where a Personal consultee is 
available, they will be provided with the study informa-
tion. The Personal consultee will be given the opportu-
nity to ask questions and discuss the study, after which 
their oral agreement will be recorded. Where a Personal 
consultee is not available, a nominated consultee will be 
identified to advise the research team. The nominated 
consultee will be the patient’s treating Trauma and 
Orthopaedic surgeon. If that surgeon is a member of the 
research team, another independent surgeon will be 
identified.
At the first appropriate time when the patient has 
regained capacity (this will usually be on the first day after 
surgery) the research associate will provide the patient 
with the study information. The patient will be given the 
opportunity to ask questions and discuss the study with 
their family and carers for as long as they require. They will 
then be asked to provide written consent for continuation 
in the study. If the patient does not wish to complete ques-
tionnaires for the study at this stage, they will be asked if 
they are happy to provide written consent for the research 
team to access and use any routinely collected nHs data, 
including those collected through the nHFD. Alternatively 
the patient can choose to decline participation completely. 
The original signed consent form will be kept in the inves-
tigator site file. Three copies of the consent forms will be 
made; one held in the patient’s medical notes, one for the 
patient and one copy for the study team.
On occasion, patients may be able to provide consent 
before their operation; for example those whose surgery 
has been delayed for clinical reasons. These patients will 
be approached by the research team before their opera-
tion for consent to participate in the study. some patients, 
whose surgery has been delayed, may still not have 
capacity, e.g., those who are acutely confused. In this 
case, the research team will approach a consultee for 
agreement that the patient participate in the study. The 
patient themselves will be approached for consent as 
soon as the clinical team deems that the patient has 
regained capacity following their operation.
Best efforts will be made to involve participants who, 
temporarily or permanently, lack the capacity in the deci-
sion to be involved in the study. The clinical team will 
make a judgement about the amount and complexity of 
the information that the participant is able to understand 
and retain on an individual basis. Appropriate informa-
tion will be communicated to the participant and updated 
as their understanding changes. At all times, the study 
team will act in accordance with the participants’ best 
interests.
Any new information that arises during the study that 
may affect participants’ willingness to take part will be 
reviewed by the Trial steering committee; if necessary 
this will be communicated to all participants and a revised 
consent form completed.
Responsibility for recording and dating both oral and 
written informed consent or agreement will be with the 
investigator, or persons designated by the investigator, 
who conducted the informed consent discussion. 
Designated responsibility should be recorded on the site 
delegation log.
recruitment. Participant recruitment began in February 
2015.
Pre-enrolment eligibility checks will be carried out by 
the study team to ensure that participants are not enrolled 
in error. Participant consent, personal or nominated con-
sultee agreement will be documented. Inclusion of the 
participant in the study will be recorded in the clinical 
notes by the research associate.
If the participant withdraws from the study com-
pletely, data collected up until the point of withdrawal 
will be included in the final analysis. Those participants 
who die before consent/agreement can be obtained will 
not be included in the study to avoid distressing the rela-
tives unnecessarily. For those participants who die before 
consent/agreement can be obtained, routinely collected 
hospital data that are useful and relevant to the trial will 
be recorded up until the patient’s death. This will be 
included in the final analysis. We will not complete par-
ticipant questionnaires or include the participants in the 
trial beyond this to avoid distressing the relatives 
unnecessarily.
Power and total sample size. sample size is calculated 
based on a superiority design. The best available evi-
dence we have from data collected during the WHiT and 
WHITE studies suggests that the standard deviation for 
EQ-5D at four months post-surgery is approximately 0.3 
points.17 The best evidence we have for what an appro-
priate minimum clinically important difference (McID) 
is for EQ-5D comes from the paper by Walters and 
Brazier.19 After a review of the appropriate literature, the 
authors estimated a median value of 0.08 for the McID 
for EQ-5D. using our best estimate of the standard devia-
tion (sd  =  0.3), this suggests a standardised effect size 
of approximately 0.24. This is reassuring, as it is exactly 
equivalent to the mean McID that Walters and Brazier 
report in their literature review, and is what we might 
classify as a ‘small to moderate effect’ based on cohen’s 
criteria.20 Taking a conservative approach, we design the 
study using a marginally smaller McID. Therefore, we 
consider values ranging from 0.07 to 0.08 (Table I).21
Assuming that the EQ-5D at four months post-surgery 
has an approximate normal distribution, which Parsons 
et al17 suggests is reasonable, and using a 1:1 allocation 
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ratio, then if the true difference between the experimen-
tal and control group EQ-5D means is in the range from 
0.07 to 0.08, we will need to recruit the below number of 
participants in each group to be able to reject the null 
hypothesis that the population means are equal with 
probability (power) 0.8 and 0.9 and type I error rate of 
5% (significance).
Taking the intermediate McID of 0.075, suggests for 
80% power, we would need to recruit 252 patients in the 
experimental arm and 252 in the control arm (544 in 
total). In this population we expect some considerable loss 
to follow-up due mainly to patient death, so we will 
assume that only 70% of recruited study participants will 
be available at the definitive end point at four months. This 
gives a total sample size of 720 for 80% power and 964 for 
90% power. The latter is recommended for scientific rigor. 
so our best estimate of the minimum sample size required 
to detect a difference between these groups is 964.
Treatment allocation. Participants will be randomised 
to one of two groups:
group one: Thompsons hemiarthroplasty;
group two: Polished taper Exeter and unitrax head.
Allocation sequences will be created using a com-
puter-generated random number sequence. Patients will 
be allocated using secure, online randomisation via a dis-
tant computer generated system administered by 
Warwick clinical Trials unit (cTu). In the event of techni-
cal difficulties, a dedicated randomisation phone line will 
be available from Warwick cTu. Participants will be 
enrolled by the operating surgeon or trial research associ-
ates. Participants will be assigned to their treatment allo-
cation prior to the time of surgery by accessing the online 
randomisation programme. This will allow for treatment 
allocation to be implemented outside of working hours.
The treatment allocation will be stratified by trial cen-
tre, age (< 80 and 80 + years) and gender, using a mini-
misation procedure implemented by Warwick cTu. The 
surgery will be performed under the care of any of the 
consultant surgeons in the collaborating centres. The 
large number of surgeons and the wide skill mix should 
eliminate the ‘surgeon effect’ such that stratification by 
surgeon is not required.22
Blinding. Participants will be blinded to the treatment 
allocation. The operating surgeon cannot be blinded to 
the allocation but will take no part in the assessment of the 
primary outcome measurement, which will be determined 
from patient interview and the clinical record. The EQ-5D is a 
patient reported measure. Patients will be kept blinded until 
the completion of the trial when the blind is broken. There 
will be no formal analysis of the success of the blinding.
leg length inequality will be performed indepen-
dently, and will be unblinded.
Trial treatments: pre-operative assessment. Participants 
will usually be assessed in the Emergency Department. 
Diagnosis of a hip fracture will be confirmed by a plain AP 
radiograph of the pelvis, and further imaging as required.
Participants will be transferred to an Orthopaedic 
Trauma ward and will receive pragmatic standard care, 
as per the nIcE guidelines.5
Trial treatments: anaesthetic technique. A regional 
or general anaesthesia technique will be used for every 
participant.
Surgical intervention. The approach and operative 
technique employed will be at the discretion of the oper-
ating surgeon.
Post-operative rehabilitation. Post-operative analgesia 
will be prescribed intra-operatively and reviewed by the 
responsible clinical teams as appropriate.
centres will aim to provide all participants with a clini-
cal review by a specialist Orthogeriatrician within 72 
hours of admission. This will include a fracture prevention 
assessment. Assessment and treatment of participants’ for 
osteoporosis will be carried out in accordance with cur-
rent nIcE guidance.23 similarly, participants’ risk of falling 
will be assessed in accordance with BOA guidance.24
Participants will be discharged from the acute 
Orthopaedic Trauma Ward at the earliest safe opportu-
nity as per routine practice and to the most appropriate 
discharge destination as determined by the multi-discipli-
nary team.
Study assessments. Table II describes the assessments 
and interventions that will be carried out during the 
period that each participant is involved in the study.
methods and assessments. Participants will be followed 
up centrally unless a site opts to collect the information 
locally.
We will use techniques to ensure minimum loss to 
follow-up - multiple contact addresses, telephone num-
bers, mobile numbers and email addresses will be col-
lected during enrolment.
We will attempt to contact the participant or next of kin 
on several occasions via telephone. If this fails, we will 
send the participant or next of kin a postal questionnaire 
to complete with a pre-paid return envelope. Finally, the 
general Practitioner of those participants who are deemed 
‘lost-to-follow-up’ will be contacted in order to attempt 
to complete it. If all these methods fail, we will class the 
participant as a non-responder for that time point.
Quality of Life (EQ-5D). EuroQol (EQ-5D-5l)15 to be col-
lected pre operatively and four months post-operatively. 
The EQ-5D 5l is a validated self-administered patient-
reported outcome measure widely used and requires less 
than ten minutes to complete. This is a generic HRQol 
Table I. Minimum clinically important difference (McID) for EQ-5D21.
Power mCID
0.07 0.075 0.08
80% 290 252 222
90% 387 337 297
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measure consisting of five dimensions, each with a five-
level answer possibility. Each combination of answers can 
be converted into a health utility score. It has good test-
retest reliability, is simple for patients to use, and gives a 
single preference-based index value for health status that 
can be used for broader cost-effectiveness comparative 
purpose. EQ-5D scores can also reasonably be collected 
from proxies (relatives and carers).
radiological leg length. leg length will be assessed by 
drawing a true horizontal transverse line between the 
centre of the contralateral femoral head and the centre of 
the prosthetic femoral head. A second line in the axis of 
the femoral shaft is drawn through the greater trochan-
ter, bisecting to the horizontal line. The vertical distance 
from the tip of the greater trochanter to horizontal is to 
be taken as the neck length. A range of 5 mm proximal or 
distal as compared with the contralateral side is consid-
ered acceptable. The outcome measure will be satisfac-
tory or unsatisfactory leg length.11
Functional status. Functional status will be assessed in 
line with the nHFD routine dataset. This will include one 
question related to walking ability indoors and outdoors 
and information of any bone protection medication taken.
Complications. Adverse events will be recorded into 
a complications reporting form at each site and sent to 
the central office monthly. These will be recorded and 
reported annually to the sponsor and ethics committee.
Data management
Data collection and management. Personal data col-
lected during the trial will be handled and stored in accor-
dance with the 1998 Data Protection Act and Warwick 
cTu standard Operating Procedures.
It is likely that some data may not be available due to 
voluntary withdrawal of participants, lack of completion 
of individual data items or general loss to follow-up. 
Where possible the reasons for missing data will be ascer-
tained and reported.
Case report forms. The case report forms (cRFs) will be 
designed by the Trial-coordinator in conjunction with 
the chief Investigator, co-Investigators and statisticians. 
Hospital sites will send original copies to Warwick cTu in 
a pre-paid envelope. Alternatively, forms can be sent elec-
tronically, using a secure nHs.net email account. Data will 
be entered onto a database by a member of the trial team, 
and will be subject to validity checks and additional data-
checking procedures in order to assure quality of data 
entry. The original cRF will be securely stored in archiving 
approved and overseen by the unit Quality Assurance 
Manager. The additional copies will be kept and stored at 
each hospital site in the Investigator site File and kept for a 
minimum of ten years, or as required by Trust regulations 
at each particular hospital site, whichever is longer.
Patient contact details and consent forms will be 
removed from the cRF booklet and the original top copy 
returned to the WHiTE 3: HEMI trial office separately to 
the cRF booklet to maintain participant anonymity, and 
only if consent has been given.
Database and management. The data collected from 
participants listed in Table I will be entered in the trial 
database. The study databases will be set up by a Warwick 
cTu computer programmer according to standard operat-
ing procedures and all specifications agreed between the 
computer Programmer, statistician and Trial co-ordinator. 
The procedure for data entry will be documented in the 
data management plan. In the case of any interim analy-
sis, the database will be frozen at the analysis time point. 
Data collected after this point will not be included in the 
interim report. We will send data collected at follow-up to 
the nHFD via a secure nHs.net email account for them to 
input using the participant DOB and nHs number as iden-
tifiers. nHs.net is a secure, encrypted way of transferring 
data recommended for use between nHs Trusts.
Data access and quality assurance. All data collected 
will be anonymised after the collection of the baseline 
demographic data, and all participants given a unique 
study number at the point of randomisation. Identifiable 
participant data will be held on a separate database and 
in a locked filing cabinet and coded with a study par-
ticipant number to tag identifiable data to the outcome 
data. names and addresses will not be disclosed to any-
one other than staff involved in running the study.
Disclosure of confidential information will only be 
given if a participant indicates an issue which may jeop-
ardise the safety of the participant or another person.
Direct access to source data/documentation may be 
required for study-related monitoring or audit by Warwick 
cTu, regulatory authorities, nHs Trust R&D staff, or ethic 
committees.
Data storage. All paper data will be stored in a desig-
nated storage facility in the clinical Trials unit at Warwick. 
Electronic data will be stored on password protected uni-
versity computers in a redistricted access building. Access 
will be restricted to authorised personnel.
Archiving of trial data. Data will be archived in accor-
dance with Warwick cTu guidance.
Table II. study assessments.
Study assessment points Baseline 4 months
core dataset Inclusion/exclusion yes  
contact details yes  
Past medical history yes  
EQ-5D yes yes
leg length yes
Operation note yes  
Discharge summary yes  
complications yes yes
nHFD Present condition yes  
Functional status pre-admission yes  
Functional status yes yes
Hospital information – admission yes  
Hospital information – surgery yes  
Hospital information – treatment yes  
Hospital information – discharge yes  
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Data analysis
Data validation. Prior to formal analysis, data will be 
checked for outliers, missing values and validated using 
the defined score ranges for all outcome measures. 
Queries will be reported to the Trial co-ordinator and 
investigated. standard statistical summaries (e.g., medi-
ans and ranges or means and variances, dependent on the 
distribution of the outcome) and graphical plots showing 
correlations will be presented for the primary outcome 
measure and all secondary outcome measures. Baseline 
data will be summarised to check comparability between 
treatment arms, and to highlight any characteristic differ-
ences between those individuals in the study, those ineli-
gible, and those eligible but withholding consent.
missing data. It seems likely that some data may not be 
available due to voluntary withdrawal of patients, lack 
of completion of individual data items or general loss to 
follow-up. Where possible the reasons for data ‘missing-
ness’ will be ascertained and reported. Although missing 
data are not expected to be a problem for this study, the 
nature and pattern of the missingness will be carefully 
considered — including in particular whether data can be 
treated as missing at random (MAR). If judged appropri-
ate, missing data will be imputed. Any imputation meth-
ods used for scores and other derived variables will be 
carefully considered and justified. If the degree of miss-
ingness is relatively low, as expected, the primary analy-
sis will be based on complete cases only (complete case 
analysis), with analysis of imputed datasets used to assess 
the sensitivity of the analysis to the missing data. Reasons 
for ineligibility, non-compliance, withdrawal or other 
protocol violations will be stated, and any patterns sum-
marised. More formal analysis, for example using logistic 
regression with ‘protocol violation’ as a response, may 
also be appropriate and aid interpretation.
Analysis of clinical effectiveness
Primary outcome. The main analysis will investigate 
differences in the primary outcome measure, EQ-5D 
(HRQol), between the two treatment groups on an 
intention-to-treat basis at four months from the index 
fracture. The differences between treatment groups will 
be assessed using a student t-test, based on a normal 
approximation for EQ-5D. Tests will be two sided and 
considered to provide evidence for a significant differ-
ence if p-values are less than 0.05 (5% significance level). 
Estimates of treatment effects will be presented with 95% 
confidence intervals.
The minimisation procedure used for randomisation 
will ensure balance in treatment allocation across recruit-
ing centres, age groups (< 80 and 80 + years) and gender. 
However, in addition to the unadjusted analyses (t-tests) 
we will also undertake regression analyses to adjust for 
any imbalance between treatment groups in patient base-
line (pre-injury) EQ-5D, age and gender. The fixed effects 
analysis (linear regression model) will also be generalised 
by adding a random effect for recruiting centre to allow 
for possible heterogeneity in patient outcomes due more 
generally to the recruiting centre. The mixed-effects 
regression will be the definitive analyses and will be 
undertaken using the specialist mixed-effects modelling 
functions available in the software package R (R Founda-
tion, vienna, Austria). EQ-5D data will be assumed to be 
approximately normally distributed; possibly after appro-
priate variance-stabilising transformation. The primary 
focus will be the comparison of the two treatment groups 
of patients, and this will be reflected in the analysis which 
will be reported together with appropriate diagnostic 
plots that check the underlying model assumptions. 
Results will be presented as mean differences between the 
trial groups, with 95% confidence intervals.
Secondary outcomes and complications. secondary 
analyses will be undertaken using the above strategy for 
approximately normally distributed outcome measures; 
length of index hospital stay (after log-transform). For 
dichotomous outcome variables, such as leg length dis-
crepancy, indicators of revision and other complications 
related to the trial interventions, mixed effects logistic 
regression analysis will be undertaken with results pre-
sented as odds ratios (and 95% confidence intervals) 
between the trial groups. The temporal patterns of 
any complications will be presented graphically and, if 
appropriate, a time-to-event analysis (Kaplan-Meier sur-
vival analysis) will be used to assess the overall risk and 
risk within individual classes of complications (e.g., revi-
sion) and death. cox’s proportional hazards regression 
will be used to test for differences in death rates between 
the trial intervention groups, after adjusting for age and 
gender. Multiple complications will be defined as two 
or more independent events, i.e., not continuations of a 
previous complication, for the same patient and will be 
identified only after discussion with the clinical team.
Plan of analysis. The statistical analysis plan (sAP) will 
be agreed with the Data management committee (DMc) 
at the start of the study. Any subsequent amendments to 
this initial sAP will be clearly stated and justified. Interim 
analyses will be performed only where directed by the 
DMc. All statistical analyses will be carried out using soft-
ware package R.
Trial organisation and oversight
Trial Oversight Committee. A Trial Oversight comm-
ittee will be convened and independently chaired in 
accordance with the university of Warwick cTu stan-
dard operating procedures. All issues pertaining to the 
management of the trial will be co-ordinated by the Trial 
steering committee. The schedule for meetings of the 
committee will be as follows:
 – Meeting one: trial commencement;
 – Meeting two: interim meeting at 50% recruitment;
 – subsequent meetings: end of trial.
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Data monitoring committee. A data monitoring com-
mittee will be convened and review data once the trial 
has recruited 50% of the target.
Trial management group. A trial management group 
will meet on a monthly basis in order to explore issues 
pertaining to the day-to-day running of the trial.
Trial registration. The trial has been registered with 
the International standard Randomised controlled Trial 
number Register. IsRcTn 39085558.
unblinding. unblinding will occur for clinical man-
agement purposes only. In exceptional circumstances 
beyond this, agreement will be sought from the chief 
Investigator and statistician before the blind is broken.
Interim analysis. Interim analysis will only be conducted 
upon the Data Monitoring committee’s request.
Indemnity/compensation/insurance. All issues of 
indemnity, compensation and insurance are detailed in 
the sponsorship statement of northumbria Healthcare 
nHs Foundation Trust.
monitoring and quality assurance policy. Quality con-
trol procedures will be undertaken during the recruitment 
and data collection phases of the study to ensure research 
is conducted, generated, recorded and reported in com-
pliance with the protocol, gcP and ethics committee. The 
chief Investigator and trial coordinator will conduct sam-
pling of the database as per the data management plan in 
order to identify any problems in trial procedures.
Dissemination and publication. The results of this trial will 
be disseminated to the trauma and orthopaedic surgery 
community via presentations at national and international 
meetings, as well as publication in peer reviewed journals.
The results will be made available to patients and the 
public via newsletters, press releases and blogs.
The trial design and report aim to be of sufficient qual-
ity to inform policy such as nIcE guidance.
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